Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TANGO III: Meropenem-Vaborbactam in HABP/VABP
NCT03006679Phase 3Withdrawn
- Sponsor
- Melinta Therapeutics
- Start
- Aug 2018
- Primary completion
- Jun 2020
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of vaborbactam in hospital-acquired bacterial pneumonia (HAP), ventilator-associated pneumonia (VAP), sponsored by Melinta Therapeutics. Planned start Aug 2018; status: withdrawn.
02
Drugs
vaborbactam
03
Conditions
hospital-acquired bacterial pneumonia (HAP)ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on NCT03006679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03006679.